Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.77 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475468 | 0.95 | PDE5A (0.85) | PDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL6477495 | 0.93 | PDE5A (0.78) | PDE5A | |
| SCHEMBL6642354 | 0.93 | PDE5A (0.77) | PDE5AHDAC1HDAC2HDAC6 | |
| SCHEMBL22028303 | 0.92 | PDE5A (0.90) | PDE5A | |
| SCHEMBL6643877 | 0.91 | PDE5A (0.76) | PDE5A | |
| SCHEMBL6642929 | 0.91 | PDE5A (0.79) | PDE5A | |
| SCHEMBL22028287 | 0.91 | PDE5A (0.81) | PDE5A | |
| SCHEMBL6640695 | 0.90 | PDE5A (0.77) | PDE5A | |
| SCHEMBL20568055 | 0.88 | PDE5A (0.88) | PDE5A | |
| SCHEMBL6643698 | 0.88 | PDE5A (0.83) | PDE5AHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9271916-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | claimed |
| US-20140187775-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-07-03 | — | — | US | claimed |
| WO-2013036081-A2 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-03-14 | — | — | WO | claimed |
| US-6962911-B2 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2005-11-08 | — | — | US | claimed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | claimed |
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | SK CHEMICALS CO., LTD. (KR) | 2003-09-11 | — | — | US | claimed |
| US-9271916-B2 | Composition for reducing skin wrinkles including PDE5 inhibitor | SK CHEMICALS CO., LTD. (KR) | 2016-03-01 | — | — | US | disclosed |
| US-20140187775-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2014-07-03 | — | — | US | disclosed |
| WO-2013036081-A2 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | SK CHEMICALS CO., LTD. (KR) | 2013-03-14 | — | — | WO | disclosed |
| EP-1257553-B1 | PYRROLOPYRIMIDINONE DERIVATIVES, PROCESS OF PREPARATION AND USE | SK CHEMICALS CO LTD (KR) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171361-A1 | Pyrrolopyrimidinone derivatives, process of preparation and use | CYP2C19, DHPS, SDHA | PDE5A 686/4885HDAC1 3087/4885HDAC2 2776/4885 |
| US-20140187775-A1 | COMPOSITION FOR REDUCING SKIN WRINKLES INCLUDING PDE5 INHIBITOR | PDE5A, PDE3B, PDE3A | PDE5A 1/4885HDAC1 467/4885HDAC2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.